Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease. The BEACON study evaluated provider-reported outcomes from 21 investigators treating 162 long-term care patients who received routine…
Discussion
June is Alzheimer’s & Brain Awareness Month, and the Alzheimer’s Association is holding a wide range of events to raise funds to fuel research and promote awareness of Alzheimer’s disease and other forms of dementia. According to the association’s website, …
Discussion
The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. Auvelity is now the only FDA-approved treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic, according to the Alzheimer’s Association. “For…
Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Alzheimer’s journey.
There is no cure for Alzheimer’s yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
